Novartis Signs $3.2B Alteogen Deal
Novartis has partnered with South Koreas Alteogen in a licensing agreement worth up to $3.22 billion. The deal provides access to technology that converts intravenous treatments into convenient subcutaneous injections.
Xurve View
Insights:
Xurve View